DNA vaccination against mutant huntingtin ameliorates the HDR6/2 diabetic phenotype

Molecular Therapy

Volumn 7, Issue 5, 2003, Pages 572-579

  Miller, Tood W ^a,b   Shirley, Thomas L ^a,b   Wolfgang, William J ^a,b   Kang, Xiaowei ^a,b   Messer, Anne ^a,b  

^a STATE UNIVERSITY OF NEW YORK   (United States)

^b WADSWORTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CELL ANTIGEN; COMPLEMENTARY DNA; DNA VACCINE; GLUCOSE; GREEN FLUORESCENT PROTEIN; HUNTINGTIN; INSULIN; NEUROTOXIN; POLYGLUTAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; BIOASSAY; CONTROLLED STUDY; DEGENERATIVE DISEASE; DIABETES MELLITUS; DISEASE COURSE; DISEASE MODEL; DISEASE SEVERITY; DRUG EFFICACY; GENE MUTATION; HUNTINGTON CHOREA; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNIZATION; IMMUNOHISTOCHEMISTRY; INSULIN DEFICIENCY; MOUSE; NONHUMAN; OBSERVATION; PANCREAS INSUFFICIENCY; PATHOGENESIS; PHENOTYPE; REVIEW; VACCINATION; WILD TYPE;

ANIMALIA;

EID: 0037562002     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1525-0016(03)00063-7     Document Type: Article

References (46)

1. Schenk, D., et al. (1999). Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400: 173-177.
2. Heppner, F. L., et al. (2001). Prevention of scrapie pathogenesis by transgenic expression of anti-prion protein antibodies. Science 294: 178-182.
3. During, M. J., et al. (2000). An oral vaccine against NMDAR1 with efficacy in experimental stroke and epilepsy. Science 287: 1453-1460.
4. Hauben, E., et al. (2000). Passive or active immunization with myelin basic protein promotes recovery from spinal cord contusion. J. Neurosci. 20: 6421-6430.
5. The Huntington's Disease Collaborative Research Group (1993). A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72: 971-983.
6. Harper, P. S. (1991). Huntington's Disease. Saunders, London.
7. Sutton, I., and Winer, J. B. (2002). The immunopathogenesis of paraneoplastic neurological syndromes. Clin. Sci. (London) 102: 475-486.
8. Levine, B., et al. (1991). Antibody-mediated clearance of alphavirus infection from neurons. Science 254: 856-860.
9. Dietzschold, B., et al. (1992). Delineation of putative mechanisms involved in antibody-mediated clearance of rabies virus from the central nervous system. Proc. Natl. Acad. Sci. USA 89: 7252-7256.
10. Byrnes, A. P., Durbin, J. E., and Griffin, D. E. (2000). Control of Sindbis virus infection by antibody in interferon-deficient mice. J. Virol. 74: 3905-3908.
11. Lecerf, J. M., et al. (2001). Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington's disease. Proc. Natl. Acad. Sci. USA 98: 4764-4769.
12. Robinson, H. L., and Torres, C. A. (1997). DNA vaccines. Semin. Immunol. 9: 271-283.
13. Perutz, M. F., Johnson, T., Suzuki, M., and Finch, J. T. (1994). Glutamine repeats as polar zippers: Their possible role in inherited neurodegenerative diseases. Proc. Natl. Acad. Sci. USA 91: 5355-5358.
14. Fain, J. N., Del Mar, N. A., Meade, C. A., Reiner, A., and Goldowitz, D. (2001). Abnormalities in the functioning of adipocytes from R6/2 mice that are transgenic for the Huntington's disease mutation. Hum. Mol. Genet. 10: 145-152.
15. Luthi-Carter, R., et al. (2002). Dysregulation of gene expression in the R6/2 model of polyglutamine disease: Parallel changes in muscle and brain. Hum. Mol. Genet. 11: 1911-1926.
16. Sathasivam, K., et al. (1999). Formation of polyglutamine inclusions in non-CNS tissue. Hum. Mol. Genet. 8: 813-822.
17. Farrer, L. A. (1985). Diabetes mellitus in Huntington disease. Clin. Genet. 27: 62-67.
18. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (2001). Report on the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 24: S5-S20.
19. Podolsky, S., Leopold, N. A., and Sax, D. S. (1972). Increased frequency of diabetes mellitus in patients with Huntington's chorea. Lancet 1: 1356-1358.
20. Podolsky, S., and Leopold, N. A. (1977). Abnormal glucose tolerance and arginine tolerance tests in Huntington's disease. Gerontology 23: 55-63.
21. Mangiarini, L., et al. (1996). Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87: 493-506.
22. Hurlbert, M. S., et al. (1999). Mice transgenic for an expanded CAG repeat in the Huntington's disease gene develop diabetes. Diabetes 48: 649-651.
23. Kazantsev, A., Preisinger, E., Dranovsky, A., Goldgaber, D., and Housman, D. (1999). Insoluble detergent-resistant aggregates form between pathological and nonpathological lengths of polyglutamine in mammalian cells. Proc. Natl. Acad. Sci. USA 96: 11404-11409.
24. Duyao, M. P., et al. (1995). Inactivation of the mouse Huntington's disease gene homolog Hdh. Science 269: 407-410.
25. Luesse, H. G., et al. (2001). Evaluation of R6/2 HD transgenic mice for therapeutic studies in Huntington's disease: Behavioral testing and impact of diabetes mellitus. Behav. Brain Res. 126: 185-195.
26. Krieg, A. M., and Davis, H. L. (2001). Enhancing vaccines with immune stimulatory CpG DNA. Curr. Opin. Mol. Ther. 3: 15-24.
27. Marsh, J. L., et al. (2000). Expanded polyglutamine peptides alone are intrinsically cytotoxic and cause neurodegeneration in Drosophila. Hum. Mol. Genet. 9: 13-25.
28. Trettel, F., et al. (2000). Dominant phenotypes produced by the HD mutation in STHdh(Q111) striatal cells. Hum. Mol. Genet. 9: 2799-2809.
29. Jana, N. R., Zemskov, E. A., Wang, G., and Nukina, N. (2001). Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release. Hum. Mol. Genet. 10: 1049-1059.
30. Parker, J. A., et al. (2001). Expanded polyglutamines in Caenorhabditis elegans cause axonal abnormalities and severe dysfunction of PLM mechanosensory neurons without cell death. Proc. Natl. Acad. Sci. USA 98: 13318-13323.
31. Gutekunst, C. A., et al. (1999). Nuclear and neuropil aggregates in Huntington's disease: Relationship to neuropathology. J. Neurosci. 19: 2522-2534.
32. Kuemmerle, S., et al. (1999). Huntington aggregates may not predict neuronal death in Huntington's disease. Ann. Neurol. 46: 842-849.
33. Saudou, F., Finkbeiner, S., Devys, D., and Greenberg, M. E. (1998). Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 95: 55-66.
34. Krieg, A. M., et al. (1995). CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374: 546-549.
35. Rabchevsky, A. G., Degos, J. D., and Dreyfus, P. A. (1999). Peripheral injections of Freund's adjuvant in mice provoke leakage of serum proteins through the blood-brain barrier without inducing reactive gliosis. Brain Res. 832: 84-96.
36. Cserr, H. F., DePasquale, M., Harling-Berg, C. J., Park, J. T., and Knopf, P. M. (1992). Afferent and efferent arms of the humoral immune response to CSF-administered albumins in a rat model with normal blood-brain barrier permeability. J. Neuroimmunol. 41: 195-202.
37. Bard, F., et al. (2000). Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 6: 916-919.
38. Morgan, D., et al. (2000). A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408: 982-985.
39. Janus, C., et al. (2000). A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408: 979-982.
40. Dodart, J. C., et al. (2002). Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat. Neurosci. 5: 452-457.
41. Birmingham, K., and Frantz, S. (2002). Set back to Alzheimer vaccine studies. Nat. Med. 8: 199-200.
42. Pfeifer, M., et al. (2002). Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science 298: 1379.
43. Sigurdsson, E. M., et al. (2002). Immunization delays the onset of prion disease in mice. Am. J. Pathol. 161: 13-17.
44. Dragatsis, I., Levine, M. S., and Zeitlin, S. (2000). Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice. Nat. Genet. 26: 300-306.
45. Manley, K., Pugh, J., and Messer, A. (1999). Instability of the CAG repeat in immortalized fibroblast cell cultures from Huntington's disease transgenic mice. Brain Res. 835: 74-79.
46. Krieg, A. M. (2000). Minding the Cs and Gs. Mol. Ther. 1: 209-210.